Synthetic Biologics Inc (SYN) 2.31 $SYN
Our 2 Healthcare Picks For April
Lowenthal Capital Partners - at Seeking Alpha - Tue Apr 14, 5:25AM CDT
SYN: 2.31 (-0.07), GSK: 46.57 (-0.67)
Synthetic Biology - Global Strategic Business Report 2015-2020
M2 - Wed Apr 08, 3:13AM CDT
Research and Markets (http://www.researchandmarkets.com/research/t3bgw8/synthetic_biology) has announced the addition of the "Synthetic Biology - Global Strategic Business Report" report to their offering. This report analyzes the worldwide markets for Synthetic Biology in US$ Thousands by the following Product Segments: Enabled Products, and Others. The report also analyzes the market by the following Application Areas: Energy and Chemicals, Biotechnology and Pharmaceuticals, and Others. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, and Rest of World. Annual estimates and forecasts are provided for the period 2014 through 2020. Also, a seven-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. The report profiles 51 companies including many key and niche players such as: Players Focused on Synthetic Biology Applications - Amyris, Inc. (US) - BP PLC. (UK) - Chromatin Inc. (US) - Evolva SA (Switzerland) - Gevo, Inc. (US) - Joule Unlimited, Inc. (US) - Metabolix (US) - MorphoSys AG (Germany) - Sapphire Energy, Inc. (US) - Solazyme, Inc. (US) - Synthetic Biologics, Inc. (US) - Synthetic Genomics, Inc. (US) Players Focused on Gene Synthesis and Tools - 454 Life Sciences (US) - Agilent Technologies Inc. (US) - ATG Biosynthetics GmbH (Germany) - DNA2.0 (US) - Epoch Life Science, Inc. (US) - Gen9, Inc. (US) - GenScript USA, Inc. (US) - Gingko Bioworks, Inc. (US) - Intrexon Corporation (US) - LC Sciences LLC (US) - Life Technologies Corp. (US) - OPXBIO, Inc. (US) - OriGene Technologies, Inc. (US) - Sangamo BioSciences, Inc. (US) - Verdezyne, Inc. (US Key Topics Covered: 1. OUTLOOK 2. INDUSTRY OVERVIEW 3. MARKET TRENDS, DRIVERS, AND ISSUES 4. KEY RESEARCH FINDINGS ON SYNTHETIC BIOLOGY 5. SYNTHETIC BIOLOGY - AN OVERVIEW 6. PRODUCT INNOVATIONS/INTRODUCTIONS 7. RECENT INDUSTRY ACTIVITY 8. FOCUS ON SELECT PLAYERS 9. GLOBAL MARKET PERSPECTIVE Total Companies Profiled: 51 (including Divisions/Subsidiaries (52) - The United States (41) - Canada (1) - Europe (
- France (1) - Germany (3) - The United Kingdom (1) - Spain (1) - Rest of Europe (2) - Asia-Pacific (Excluding Japan) (2) For more information visit http://www.researchandmarkets.com/research/t3...ic_biology
SYN: 2.31 (-0.07), AMRS: 2.61 (unch), A: 42.71 (-0.18), SGMO: 14.37 (-0.03), XON: 44.53 (+0.36), GEVO: 2.79 (+0.78), SZYM: 3.71 (-0.06)
Synthetic Biologics' SYN-004 Clinical Data for Protection of Microbiome Selected for Poster Presentation at American Society of Microbiology 2015
PR Newswire - Wed Apr 01, 5:56AM CDT
Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of pathogen-specific therapies for serious infections and diseases, with a focus on protecting the microbiome, today announced that clinical data supporting the development of SYN-004, the Company's candidate therapy designed to degrade certain beta-lactam intravenous (IV) antibiotics within the gastrointestinal (GI) tract and maintain the natural balance of the gut microbiome for the prevention of C. difficile infection, antibiotic-associated diarrhea and secondary antibiotic-resistant infections, has been selected for presentation during the 115th General Meeting of the American Society of Microbiology (ASM2015) in New Orleans, LA on May 30-June 1.
SYN: 2.31 (-0.07), XON: 44.53 (+0.36)
Premarket Gainers / Losers as of 9:10 am
Seeking Alpha - at Seeking Alpha - Mon Mar 30, 8:11AM CDT
BDSI: 9.26 (+0.12), CRMD: 8.86 (-0.28), NCFT: 25.87 (+0.17), LEJU: 9.16 (+0.65), CTRX: 59.46 (-0.11), ZIOP: 10.88 (+0.03), ADXS: 22.18 (+0.10), CNAT: 6.31 (-0.15), XON: 44.53 (+0.36), BBEP: 6.40 (-0.10), ADMP: 4.66 (-0.01), CLDN: 13.59 (-2.77), ASPX: 100.79 (+0.09), HPTX: 45.96 (-0.18), GENE: 4.88 (-0.05), SYN: 2.31 (-0.07), ICEL: 16.47 (-0.02), HZNP: 30.96 (+0.10), OHRP: 2.72 (+0.08), SFUN: 7.82 (+0.64), CNET: 1.56 (unch)
Synthetic Biologics Initiates Phase 2a Clinical Trial of SYN-004 to Protect the Microbiome and Prevent C. difficile
PR Newswire - Mon Mar 30, 5:57AM CDT
Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of pathogen-specific therapies for serious infections and diseases, with a focus on protecting the microbiome, today announced the initiation of a Phase 2a clinical trial to evaluate the gastrointestinal (GI) antibiotic-degrading effects and the safety of SYN-004, the Company's investigational oral beta-lactamase enzyme designed to protect the microbiome and prevent C. difficile infection (CDI). C. difficile is the leading type of hospital acquired infection and is frequently associated with intravenous (IV) antibiotic treatment. Beta-lactam antibiotics are a mainstay in hospital infection management, and include commonly used penicillin and cephalosporin antibiotics, such as ceftriaxone.
SYN: 2.31 (-0.07), XON: 44.53 (+0.36)
Cough Therapeutics Pipeline Review 2015 Featuring 34 Companies
M2 - Wed Mar 25, 12:00PM CDT
Research and Markets (http://www.researchandmarkets.com/research/qpt4xp/cough_pipeline) has announced the addition of the "Cough - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Cough, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Cough and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Afferent Pharmaceuticals, Inc. - Ahn-Gook Pharmaceutical Co., Ltd. - Alitair Pharmaceuticals, Inc. - Ario Pharma Ltd - AUS Bio Limited - Beijing Minhai Biotechnology Co., Ltd - Beijing Tiantan Biological Products Co., Ltd. - Bharat Biotech International Limited - Biological E. Limited - Daewoong Pharmaceutical Co., Ltd. - Daiichi Sankyo Company, Limited - DBV Technologies S.A. - GlaxoSmithKline plc - Glenmark Pharmaceuticals Ltd. - Green Cross Corporation - Hanmi Pharmaceuticals, Co. Ltd. - Hydra Biosciences, Inc. - Hyundai Pharmaceutical Co., Ltd. - Indian Immunologicals Limited - LG Life Sciences, Ltd. - NanoBio Corporation - Neos Therapeutics, Inc. - Novartis AG - Orbis Biosciences, Inc. - Panacea Biotec Limited - Sanofi - Sanofi Pasteur SA - Serum Institute of India Limited - Sinovac Biotech Ltd. - Synthetic Biologics, Inc. For more information visit http://www.researchandmarkets.com/research/qp...h_pipeline
SYN: 2.31 (-0.07), GSK: 46.57 (-0.67), SVA: 5.06 (+0.10), NVS: 103.45 (-0.62)
Synthetic Biologics Announces Positive Pharmacokinetics Data from Phase 1a and 1b Trials of SYN-004 to Protect the Microbiome and Prevent C. difficile Infection
PR Newswire - Thu Mar 19, 5:57AM CDT
Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of pathogen-specific therapies for serious infections and diseases, with a focus on protecting the microbiome, today announced positive pharmacokinetics (PK) results from both the Phase 1a and 1b studies of SYN-004, which is being developed to protect the microbiome and prevent Clostridium difficile (C. difficile) infection.
SYN: 2.31 (-0.07), XON: 44.53 (+0.36)
Synthetic Biologics' (SYN) CEO Jeff Riley on Q4 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Mon Mar 16, 11:15AM CDT
SYN: 2.31 (-0.07)
Stocks Coverage on the Health Care Sector - AstraZeneca, Novartis, Raptor Pharma, Synthetic Biologics, and BioDelivery Sciences Intl.
PR Newswire - Mon Mar 16, 7:30AM CDT
Editor Note: For more information about this release, please scroll to bottom.
BDSI: 9.26 (+0.12), SYN: 2.31 (-0.07), RPTP: 10.56 (-0.17), AZN: 73.35 (+0.65), NVS: 103.45 (-0.62)
Synthetic Biologics FY14 results
Seeking Alpha - at Seeking Alpha - Mon Mar 16, 7:26AM CDT
SYN: 2.31 (-0.07)
Synthetic Biologics reports FY14 results
Seeking Alpha - at Seeking Alpha - Mon Mar 16, 6:02AM CDT
SYN: 2.31 (-0.07)
Synthetic Biologics Reports Year End 2014 Financial Results and Operational Highlights
PR Newswire - Mon Mar 16, 5:56AM CDT
Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of pathogen-specific therapies for serious infections and diseases, with a focus on protecting the microbiome, today reported financial results for the year ended December 31, 2014, and provided an operational update.
SYN: 2.31 (-0.07), XON: 44.53 (+0.36)
Griffin Securities' Keith Markey Thinks These 5 Stocks Have Substantial Upside
Life Sciences Report - Seeking Alpha - Fri Mar 13, 9:10AM CDT
For Keith Markey of Griffin Securities, the science is paramount. Without understanding the underlying basis for activity, safety and efficacy, there's just no betting on a biotech stock. Over the last 25 years, Markey has seen nearly every type of...
SYN: 2.31 (-0.07), ZIOP: 10.88 (+0.03), UNIS: 3.79 (-0.12), FCSC: 4.01 (+0.01), XON: 44.53 (+0.36), MNKD: 4.90 (-0.09)
Next Week In Biotech: Vertex PDUFA, Organon Ad Comm
SA Editor Mike Taylor - Seeking Alpha - Fri Mar 13, 8:00AM CDT
Every Friday morning, Seeking Alpha posts a calendar of the next week's expected biotech events to start a forward-looking conversation. Please be aware that dates and events can be subject to change. Please let us know in a comment or message if you...
BDSI: 9.26 (+0.12), VRTX: 132.85 (+0.65), CERU: 5.99 (-0.20), FOMX: 10.94 (-0.02), ONTX: 2.48 (-0.05), PFNX: 15.12 (+0.42), OMER: 24.41 (-0.15), PGNX: 6.33 (-0.12), SYN: 2.31 (-0.07), VCYT: 8.15 (+0.05), STEM: 0.82 (-0.06), APRI: 1.77 (-0.02), KPTI: 32.24 (-0.60)
Synthetic Biologics' SYN-004 Data for Protection of Microbiome Selected for Late-Breaking Poster Presentation at Digestive Disease Week® 2015
PR Newswire - Wed Mar 11, 5:56AM CDT
Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of pathogen-specific therapies for serious infections and diseases, with a focus on protecting the microbiome, today announced that preclinical results supporting the development of SYN-004, the Company's candidate therapy designed to degrade intravenous (IV) antibiotics within the gastrointestinal (GI) tract and maintain the natural balance of the gut microbiome for the prevention of C. difficile infection, will be presented during Digestive Disease Week® (DDW) 2015 in Washington DC on May 16-19.
SYN: 2.31 (-0.07), XON: 44.53 (+0.36)
Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Tue Mar 10, 11:45AM CDT
HTBX: 7.71 (-0.64), CTRV: 3.13 (-0.07), AKRX: 53.70 (-1.69), BRSS: 15.30 (+0.25), CASI: 1.52 (+0.03), JOB: 0.84 (+0.04), LL: 33.86 (+0.50), MIND: 4.97 (+0.05), BBNK: 27.26 (+0.36), WPRT: 4.39 (+0.01), URBN: 42.17 (+0.03), OCC: 4.18 (-0.04), SYN: 2.31 (-0.07), IDT: 17.66 (unch), GERN: 4.20 (-0.04), TITN: 14.25 (+0.15), IMPV: 47.68 (-0.88), NNBR: 24.82 (+0.05), REPH: 10.71 (-0.78), VPCO: 0.80 (unch)
Synthetic Biologics to Report Year End 2014 Financial Results
PR Newswire - Mon Mar 09, 5:57AM CDT
Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of pathogen-specific therapies for serious infections and diseases, with a focus on protecting the microbiome, announced today that the Company intends to release its financial results for the year ended December 31, 2014 on Monday, March 16, 2015. The Company will also hold an investor conference call on Monday, March 16th, at 8:30 a.m. EDT.
SYN: 2.31 (-0.07), XON: 44.53 (+0.36)
Synthetic Biologics to Present at the 27th Annual ROTH Conference
PR Newswire - Tue Mar 03, 5:57AM CST
Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of pathogen-specific therapies for serious infections and diseases, with a focus on protecting the microbiome, announced today that Jeffrey Riley, Chief Executive Officer, is scheduled to present at the 27th Annual ROTH Conference being held on March 8-11, 2015 at the Ritz-Carlton, Laguna Niguel in Dana Point, CA. Mr. Riley is scheduled to present on Tuesday, March 10, 2015 at 1:00 p.m. (Pacific Time).
SYN: 2.31 (-0.07), XON: 44.53 (+0.36)
Our 2 Healthcare Picks For April
Lowenthal Capital Partners - at Seeking Alpha - Tue Apr 14, 5:25AM CDT
SYN: 2.31 (-0.07), GSK: 46.57 (-0.67)
Synthetic Biology - Global Strategic Business Report 2015-2020
M2 - Wed Apr 08, 3:13AM CDT
Research and Markets (http://www.researchandmarkets.com/research/t3bgw8/synthetic_biology) has announced the addition of the "Synthetic Biology - Global Strategic Business Report" report to their offering. This report analyzes the worldwide markets for Synthetic Biology in US$ Thousands by the following Product Segments: Enabled Products, and Others. The report also analyzes the market by the following Application Areas: Energy and Chemicals, Biotechnology and Pharmaceuticals, and Others. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, and Rest of World. Annual estimates and forecasts are provided for the period 2014 through 2020. Also, a seven-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. The report profiles 51 companies including many key and niche players such as: Players Focused on Synthetic Biology Applications - Amyris, Inc. (US) - BP PLC. (UK) - Chromatin Inc. (US) - Evolva SA (Switzerland) - Gevo, Inc. (US) - Joule Unlimited, Inc. (US) - Metabolix (US) - MorphoSys AG (Germany) - Sapphire Energy, Inc. (US) - Solazyme, Inc. (US) - Synthetic Biologics, Inc. (US) - Synthetic Genomics, Inc. (US) Players Focused on Gene Synthesis and Tools - 454 Life Sciences (US) - Agilent Technologies Inc. (US) - ATG Biosynthetics GmbH (Germany) - DNA2.0 (US) - Epoch Life Science, Inc. (US) - Gen9, Inc. (US) - GenScript USA, Inc. (US) - Gingko Bioworks, Inc. (US) - Intrexon Corporation (US) - LC Sciences LLC (US) - Life Technologies Corp. (US) - OPXBIO, Inc. (US) - OriGene Technologies, Inc. (US) - Sangamo BioSciences, Inc. (US) - Verdezyne, Inc. (US Key Topics Covered: 1. OUTLOOK 2. INDUSTRY OVERVIEW 3. MARKET TRENDS, DRIVERS, AND ISSUES 4. KEY RESEARCH FINDINGS ON SYNTHETIC BIOLOGY 5. SYNTHETIC BIOLOGY - AN OVERVIEW 6. PRODUCT INNOVATIONS/INTRODUCTIONS 7. RECENT INDUSTRY ACTIVITY 8. FOCUS ON SELECT PLAYERS 9. GLOBAL MARKET PERSPECTIVE Total Companies Profiled: 51 (including Divisions/Subsidiaries (52) - The United States (41) - Canada (1) - Europe (
- France (1) - Germany (3) - The United Kingdom (1) - Spain (1) - Rest of Europe (2) - Asia-Pacific (Excluding Japan) (2) For more information visit http://www.researchandmarkets.com/research/t3...ic_biology SYN: 2.31 (-0.07), AMRS: 2.61 (unch), A: 42.71 (-0.18), SGMO: 14.37 (-0.03), XON: 44.53 (+0.36), GEVO: 2.79 (+0.78), SZYM: 3.71 (-0.06)
Synthetic Biologics' SYN-004 Clinical Data for Protection of Microbiome Selected for Poster Presentation at American Society of Microbiology 2015
PR Newswire - Wed Apr 01, 5:56AM CDT
Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of pathogen-specific therapies for serious infections and diseases, with a focus on protecting the microbiome, today announced that clinical data supporting the development of SYN-004, the Company's candidate therapy designed to degrade certain beta-lactam intravenous (IV) antibiotics within the gastrointestinal (GI) tract and maintain the natural balance of the gut microbiome for the prevention of C. difficile infection, antibiotic-associated diarrhea and secondary antibiotic-resistant infections, has been selected for presentation during the 115th General Meeting of the American Society of Microbiology (ASM2015) in New Orleans, LA on May 30-June 1.
SYN: 2.31 (-0.07), XON: 44.53 (+0.36)
Premarket Gainers / Losers as of 9:10 am
Seeking Alpha - at Seeking Alpha - Mon Mar 30, 8:11AM CDT
BDSI: 9.26 (+0.12), CRMD: 8.86 (-0.28), NCFT: 25.87 (+0.17), LEJU: 9.16 (+0.65), CTRX: 59.46 (-0.11), ZIOP: 10.88 (+0.03), ADXS: 22.18 (+0.10), CNAT: 6.31 (-0.15), XON: 44.53 (+0.36), BBEP: 6.40 (-0.10), ADMP: 4.66 (-0.01), CLDN: 13.59 (-2.77), ASPX: 100.79 (+0.09), HPTX: 45.96 (-0.18), GENE: 4.88 (-0.05), SYN: 2.31 (-0.07), ICEL: 16.47 (-0.02), HZNP: 30.96 (+0.10), OHRP: 2.72 (+0.08), SFUN: 7.82 (+0.64), CNET: 1.56 (unch)
Synthetic Biologics Initiates Phase 2a Clinical Trial of SYN-004 to Protect the Microbiome and Prevent C. difficile
PR Newswire - Mon Mar 30, 5:57AM CDT
Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of pathogen-specific therapies for serious infections and diseases, with a focus on protecting the microbiome, today announced the initiation of a Phase 2a clinical trial to evaluate the gastrointestinal (GI) antibiotic-degrading effects and the safety of SYN-004, the Company's investigational oral beta-lactamase enzyme designed to protect the microbiome and prevent C. difficile infection (CDI). C. difficile is the leading type of hospital acquired infection and is frequently associated with intravenous (IV) antibiotic treatment. Beta-lactam antibiotics are a mainstay in hospital infection management, and include commonly used penicillin and cephalosporin antibiotics, such as ceftriaxone.
SYN: 2.31 (-0.07), XON: 44.53 (+0.36)
Cough Therapeutics Pipeline Review 2015 Featuring 34 Companies
M2 - Wed Mar 25, 12:00PM CDT
Research and Markets (http://www.researchandmarkets.com/research/qpt4xp/cough_pipeline) has announced the addition of the "Cough - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Cough, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Cough and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Afferent Pharmaceuticals, Inc. - Ahn-Gook Pharmaceutical Co., Ltd. - Alitair Pharmaceuticals, Inc. - Ario Pharma Ltd - AUS Bio Limited - Beijing Minhai Biotechnology Co., Ltd - Beijing Tiantan Biological Products Co., Ltd. - Bharat Biotech International Limited - Biological E. Limited - Daewoong Pharmaceutical Co., Ltd. - Daiichi Sankyo Company, Limited - DBV Technologies S.A. - GlaxoSmithKline plc - Glenmark Pharmaceuticals Ltd. - Green Cross Corporation - Hanmi Pharmaceuticals, Co. Ltd. - Hydra Biosciences, Inc. - Hyundai Pharmaceutical Co., Ltd. - Indian Immunologicals Limited - LG Life Sciences, Ltd. - NanoBio Corporation - Neos Therapeutics, Inc. - Novartis AG - Orbis Biosciences, Inc. - Panacea Biotec Limited - Sanofi - Sanofi Pasteur SA - Serum Institute of India Limited - Sinovac Biotech Ltd. - Synthetic Biologics, Inc. For more information visit http://www.researchandmarkets.com/research/qp...h_pipeline
SYN: 2.31 (-0.07), GSK: 46.57 (-0.67), SVA: 5.06 (+0.10), NVS: 103.45 (-0.62)
Synthetic Biologics Announces Positive Pharmacokinetics Data from Phase 1a and 1b Trials of SYN-004 to Protect the Microbiome and Prevent C. difficile Infection
PR Newswire - Thu Mar 19, 5:57AM CDT
Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of pathogen-specific therapies for serious infections and diseases, with a focus on protecting the microbiome, today announced positive pharmacokinetics (PK) results from both the Phase 1a and 1b studies of SYN-004, which is being developed to protect the microbiome and prevent Clostridium difficile (C. difficile) infection.
SYN: 2.31 (-0.07), XON: 44.53 (+0.36)
Synthetic Biologics' (SYN) CEO Jeff Riley on Q4 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Mon Mar 16, 11:15AM CDT
SYN: 2.31 (-0.07)
Stocks Coverage on the Health Care Sector - AstraZeneca, Novartis, Raptor Pharma, Synthetic Biologics, and BioDelivery Sciences Intl.
PR Newswire - Mon Mar 16, 7:30AM CDT
Editor Note: For more information about this release, please scroll to bottom.
BDSI: 9.26 (+0.12), SYN: 2.31 (-0.07), RPTP: 10.56 (-0.17), AZN: 73.35 (+0.65), NVS: 103.45 (-0.62)
Synthetic Biologics FY14 results
Seeking Alpha - at Seeking Alpha - Mon Mar 16, 7:26AM CDT
SYN: 2.31 (-0.07)
Synthetic Biologics reports FY14 results
Seeking Alpha - at Seeking Alpha - Mon Mar 16, 6:02AM CDT
SYN: 2.31 (-0.07)
Synthetic Biologics Reports Year End 2014 Financial Results and Operational Highlights
PR Newswire - Mon Mar 16, 5:56AM CDT
Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of pathogen-specific therapies for serious infections and diseases, with a focus on protecting the microbiome, today reported financial results for the year ended December 31, 2014, and provided an operational update.
SYN: 2.31 (-0.07), XON: 44.53 (+0.36)
Griffin Securities' Keith Markey Thinks These 5 Stocks Have Substantial Upside
Life Sciences Report - Seeking Alpha - Fri Mar 13, 9:10AM CDT
For Keith Markey of Griffin Securities, the science is paramount. Without understanding the underlying basis for activity, safety and efficacy, there's just no betting on a biotech stock. Over the last 25 years, Markey has seen nearly every type of...
SYN: 2.31 (-0.07), ZIOP: 10.88 (+0.03), UNIS: 3.79 (-0.12), FCSC: 4.01 (+0.01), XON: 44.53 (+0.36), MNKD: 4.90 (-0.09)
Next Week In Biotech: Vertex PDUFA, Organon Ad Comm
SA Editor Mike Taylor - Seeking Alpha - Fri Mar 13, 8:00AM CDT
Every Friday morning, Seeking Alpha posts a calendar of the next week's expected biotech events to start a forward-looking conversation. Please be aware that dates and events can be subject to change. Please let us know in a comment or message if you...
BDSI: 9.26 (+0.12), VRTX: 132.85 (+0.65), CERU: 5.99 (-0.20), FOMX: 10.94 (-0.02), ONTX: 2.48 (-0.05), PFNX: 15.12 (+0.42), OMER: 24.41 (-0.15), PGNX: 6.33 (-0.12), SYN: 2.31 (-0.07), VCYT: 8.15 (+0.05), STEM: 0.82 (-0.06), APRI: 1.77 (-0.02), KPTI: 32.24 (-0.60)
Synthetic Biologics' SYN-004 Data for Protection of Microbiome Selected for Late-Breaking Poster Presentation at Digestive Disease Week® 2015
PR Newswire - Wed Mar 11, 5:56AM CDT
Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of pathogen-specific therapies for serious infections and diseases, with a focus on protecting the microbiome, today announced that preclinical results supporting the development of SYN-004, the Company's candidate therapy designed to degrade intravenous (IV) antibiotics within the gastrointestinal (GI) tract and maintain the natural balance of the gut microbiome for the prevention of C. difficile infection, will be presented during Digestive Disease Week® (DDW) 2015 in Washington DC on May 16-19.
SYN: 2.31 (-0.07), XON: 44.53 (+0.36)
Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Tue Mar 10, 11:45AM CDT
HTBX: 7.71 (-0.64), CTRV: 3.13 (-0.07), AKRX: 53.70 (-1.69), BRSS: 15.30 (+0.25), CASI: 1.52 (+0.03), JOB: 0.84 (+0.04), LL: 33.86 (+0.50), MIND: 4.97 (+0.05), BBNK: 27.26 (+0.36), WPRT: 4.39 (+0.01), URBN: 42.17 (+0.03), OCC: 4.18 (-0.04), SYN: 2.31 (-0.07), IDT: 17.66 (unch), GERN: 4.20 (-0.04), TITN: 14.25 (+0.15), IMPV: 47.68 (-0.88), NNBR: 24.82 (+0.05), REPH: 10.71 (-0.78), VPCO: 0.80 (unch)
Synthetic Biologics to Report Year End 2014 Financial Results
PR Newswire - Mon Mar 09, 5:57AM CDT
Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of pathogen-specific therapies for serious infections and diseases, with a focus on protecting the microbiome, announced today that the Company intends to release its financial results for the year ended December 31, 2014 on Monday, March 16, 2015. The Company will also hold an investor conference call on Monday, March 16th, at 8:30 a.m. EDT.
SYN: 2.31 (-0.07), XON: 44.53 (+0.36)
Synthetic Biologics to Present at the 27th Annual ROTH Conference
PR Newswire - Tue Mar 03, 5:57AM CST
Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of pathogen-specific therapies for serious infections and diseases, with a focus on protecting the microbiome, announced today that Jeffrey Riley, Chief Executive Officer, is scheduled to present at the 27th Annual ROTH Conference being held on March 8-11, 2015 at the Ritz-Carlton, Laguna Niguel in Dana Point, CA. Mr. Riley is scheduled to present on Tuesday, March 10, 2015 at 1:00 p.m. (Pacific Time).
SYN: 2.31 (-0.07), XON: 44.53 (+0.36)
